M. C. Qasem *, N. Miu **, M. Mărgescu **
* Dr. MiMI COSTIN QASEM, Emiratele Arabe Unite, RAk, Spitalul SAQR, doctorand la UMF Cluj
** Prof. dr. NICOLAE MIU, Clinica Pediatrie II, Cluj-Napoca
** Dr. Mircea MĂRGESCU, Clinica Pediatrie II, Cluj-Napoca
Abstract
The purpose of this study is to asses the efficiency of Clarithromicine versus Erithromicine in therapy of Mycoplasma Pneumoniae infections using 2 sets of pacients at who the diagnosis was made by correlating epidemiological, clinical, imagistical data, by standing out specific antibodies and by isolating (when is possible} the pathogenic factor. This study shows an higher efficiency of Clarithromicine both, in vitro and in vivo, proven by faster improvement of clinical fea tures, complete bacteriological eradication, with shortened hospitalisation, lower adverse events, higher compliance at the same cost – all these facts are reasons for choosing Clarithromicine as first antibiotic in Mycoplasma pneumoniae infection.